Want to see TSE:NRX full AI Analyst Report?
Top Page
NurExone Biologic
(NRX)
Select Model
Select Model
Rating:46Neutral
Price Target:
C$0.63
▲(25.40% Upside)
Action:Reiterated
Date:08/29/26
The score is held down primarily by weak financial performance (pre-revenue status, significant losses, and persistent cash burn implying continued financing needs). Technicals are slightly supportive in the near term but remain mixed versus longer-term averages, and valuation is constrained by negative earnings and no dividend yield data.
Positive Factors
Exosome CNS platform
A focused exosome platform gives NurExone a reusable development foundation across spinal cord injury and broader CNS indications. If the technology translates clinically, multiple pipeline concepts could create more than one path to future asset value and partnerships.
Negative Factors
Pre-revenue business model
NurExone has not yet established commercial revenue, so its financial outlook depends on advancing candidates toward approval and eventual monetization. Until that occurs, operating performance cannot be supported by recurring product sales, increasing execution and development risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Exosome CNS platform
A focused exosome platform gives NurExone a reusable development foundation across spinal cord injury and broader CNS indications. If the technology translates clinically, multiple pipeline concepts could create more than one path to future asset value and partnerships.
Read all positive factors
NurExone Biologic (NRX) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$46.97M
Dividend YieldN/A
Average Volume (3M)27.70K
Price to Earnings (P/E)―
Beta (1Y)0.04
Revenue GrowthN/A
EPS Growth19.02%
CountryCA
Employees17
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.08
Shares Outstanding73,395,850
10 Day Avg. Volume28,008
30 Day Avg. Volume27,703
Financial Highlights & Ratios
PEG Ratio-1.72
Price to Book (P/B)13.94
Price to Sales (P/S)0.00
P/FCF Ratio-8.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.06
Revenue Forecast (FY)N/A
NurExone Biologic Business Overview & Revenue Model
Company Description
NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical d...
How the Company Makes Money
As a preclinical-stage biotechnology company, NurExone Biologic does not publicly report product sales from approved therapies; its business model is primarily centered on advancing its exosome-based drug candidates through research and developmen...
NurExone Biologic Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
56
Neutral
Cash Flow
24
Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -6.17M | -4.94M | -3.60M | -8.12M | -1.68M |
| Net Income | -6.38M | -5.04M | -3.64M | -8.17M | -1.62M |
Balance Sheet | |||||
| Total Assets | 4.08M | 2.44M | 2.17M | 2.79M | 2.81M |
| Cash, Cash Equivalents and Short-Term Investments | 2.14M | 700.00K | 541.00K | 2.46M | 2.21M |
| Total Debt | 108.00K | 33.00K | 20.00K | 44.00K | 1.03M |
| Total Liabilities | 1.32M | 680.00K | 1.98M | 698.00K | 1.64M |
| Stockholders Equity | 2.76M | 1.76M | 189.00K | 2.10M | 1.17M |
Cash Flow | |||||
| Free Cash Flow | -4.57M | -5.54M | -3.06M | -3.90M | -1.21M |
| Operating Cash Flow | -4.51M | -4.89M | -2.94M | -3.85M | -1.21M |
| Investing Cash Flow | -55.00K | -658.00K | -97.00K | -89.00K | 0.00 |
| Financing Cash Flow | 5.83M | 5.88M | 1.13M | 4.29M | 3.40M |
NurExone Biologic Technical Analysis
Positive
0.50
Price Trends
0.53
Positive
0.56
Positive
0.61
Positive
Market Momentum
0.02
Negative
63.26
Neutral
60.32
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:NRX, the sentiment is Positive. The current price of 0.5 is below the 20-day moving average (MA) of 0.55, below the 50-day MA of 0.53, and below the 200-day MA of 0.61, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 63.26 is Neutral, neither overbought nor oversold. The STOCH value of 60.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:NRX.
NurExone Biologic Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | C$42.89M | -0.29 | -147.92% | ― | ― | 85.31% | |
48 Neutral | C$677.28K | 1.71 | 34.52% | ― | ― | ― | |
47 Neutral | C$14.83M | -3.04 | 92.37% | ― | ― | 16.04% | |
46 Neutral | C$46.97M | -5.76 | -334.08% | ― | ― | 19.02% | |
46 Neutral | C$36.48M | -2.13 | -360.29% | ― | ― | -33.27% | |
43 Neutral | C$41.54M | -3.13 | 55.85% | ― | ― | 49.13% |
* General Sector Average
TSE:NRX
NurExone Biologic
0.64
-0.17
-20.99%
TSE:MDNA
Medicenna Therapeutics Corp
0.47
-0.59
-55.66%
TSE:BCT
BriaCell Therapeutics
4.93
-6.05
-55.10%
TSE:HEM
Hemostemix
0.08
-0.05
-40.00%
TSE:SVA
Sernova
0.11
-0.07
-38.89%
TSE:VXL
Vaxil Bio
0.17
0.00
0.00%
NurExone Biologic Corporate Events
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and FinancingStock Split
NurExone advances exosome programs as R&D spend rises and new financing secured
Positive
Aug 31, 2026
NurExone reported second-quarter 2026 results showing higher research and development spending of US$0.75 million, driven by advancement of its ExoPTEN program, while general and administrative expenses fell to US$0.93 million on lower professiona...
Business Operations and Strategy
NurExone to Spotlight Exosome Platform at Moody Capital Disruptive Growth Conference
Positive
Aug 28, 2026
NurExone Biologic Inc. will present at the Moody Capital Solutions 2026 Disruptive Growth Life Sciences Conference in New York, where Co-Founder and Chairman Yoram Drucker will deliver an investor presentation and hold one-on-one meetings. The co...
Business Operations and StrategyDelistings and Listing ChangesShareholder MeetingsStock Split
NurExone Seeks Shareholder Approval for Share Consolidation to Support U.S. Listing Bid
Positive
Aug 21, 2026
NurExone Biologic has called an annual general and special meeting for September 15, 2026, where shareholders will vote on a proposed consolidation of its common shares at a ratio of up to 30 pre-consolidation shares for one post-consolidation sha...
Business Operations and StrategyPrivate Placements and Financing
NurExone Raises C$1.07 Million in Private Placement to Support Regenerative Therapy Push
Positive
Aug 20, 2026
NurExone Biologic has closed a non-brokered private placement of 1,938,326 units at C$0.55 per unit, raising approximately C$1.07 million in gross proceeds, subject to final approval from the TSX Venture Exchange. The funds are earmarked for gener...
Business Operations and Strategy
NurExone Preclinical Data Bolster Neuroprotective Case for ExoPTEN in Spinal Cord Injury
Positive
Aug 14, 2026
NurExone Biologic reported new preclinical tissue-analysis data indicating that animals treated with its exosome-based candidate ExoPTEN showed significantly higher numbers of myelin-positive (MBP) cells on both sides of a traumatic spinal cord in...
Business Operations and Strategy
NurExone Strikes Exclusive U.S. GMP Exosome Manufacturing Pact with Made Scientific
Positive
Aug 12, 2026
NurExone Biologic, through its U.S. subsidiary Exo‑Top, has signed a binding memorandum of understanding with Made Scientific to establish an exclusive U.S. GMP manufacturing and commercial exosome supply partnership. The parties plan to tra...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.